ArrePath receives $20 million seed financing to advance its machine learning-based platform for novel anti-infectives
ArrePath announced that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome AMR. The Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures co-led the financing, which also included Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures. Furthermore, the company also announced that Dr. Lloyd Payne has been named President and CEO. Dr. Payne, who serves on the Novo REPAIR Impact Fund Scientific Selection Board and the AMR Action Fund Scientific Advisory Board, brings more than 25 years of scientific and business leadership in the discovery and development of anti-infectives.
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections, which result in at least 1.27 million deaths, annually (according to recent analysis of data from 2019 published in The Lancet, The GRAM Report). New classes of antibiotics that more effectively treat drug resistant infections and overcome antimicrobial resistance are urgently needed. ArrePath’s approach leverages a novel technology platform to enable the discovery and development of new and differentiated antibiotics by decoding the complex behavior of bacteria when exposed to new chemical entities (known as ‘bacterial autopsies’), leading to the efficient elucidation of biological mechanisms of action. Utilizing proprietary machine learning and imaging technologies, ArrePath’s platform enables an unprecedented ability to identify, optimize, and rapidly develop new classes of anti-infectives with differentiated mechanisms of action compared to those exhibited by existing drugs.
Read more: https://www.businesswire.com/news/home/20220303005116/en/ArrePath-Announces-20-Million-Seed-Financing-to-Advance-its-Machine-Learning-based-Platform-for-Discovery-of-Novel-Anti-infectives-Addressing-Antimicrobial-Resistance?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark